French pharmaceutical giant Sanofi announced that Plexram sodium injections have been officially approved domestically to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome on the basis of diet control. This drug is the world's first small interfering RNA drug that acts on an innovative target of APOC3 mRNA.

French pharmaceutical giant Sanofi announced that Plexram sodium injections have been officially approved domestically to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome on the basis of diet control. This drug is the world's first small interfering RNA drug that acts on an innovative target of APOC3 mRNA.